Qube Research & Technologies (QRT)
ENGN icon

Qube Research & Technologies (QRT)’s enGene Therapeutics ENGN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14
Closed -$237 – 4040
2024
Q1 		$237 Buy
+14
New +$171 ﹤0.01% 4128

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ENGN Position: Q2 2024 in Review

Qube Research & Technologies (QRT) sold out of enGene Therapeutics (ENGN) in Q2 2024, closing a stake of 14 shares — an estimated $237 sold.

Qube Research & Technologies (QRT) first reported a position in ENGN in Q1 2024 and held it in 1 quarter. The position peaked at $237 in Q1 2024. 30 funds tracked by Wall St. Rank hold ENGN as of Q2 2024.

  • Qube Research & Technologies (QRT) reported no remaining enGene Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 14 enGene Therapeutics shares in Q2 2024, an estimated $237.
  • Qube Research & Technologies (QRT) first reported a position in enGene Therapeutics in Q1 2024 and held it in 1 quarter.
  • Qube Research & Technologies (QRT)'s enGene Therapeutics position peaked at $237 in Q1 2024.
  • 30 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2024, filed 14 Aug 2024.